Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes

Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 102:10610–10615,2005

Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Blüher M: Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339:430–436,2006

Zvonic S, Lefevre M, Kilroy G, Floyd ZE, DeLany JP, Kheterpal I, Gravois A, Dow R, White A, Wu X, Gimble JM: Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics 6:18–28,2007

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23 (Suppl. 1):S4–S19,2000

Oberbach A, Tönjes A, Klöting N, Fasshauer M, Kratzsch J, Busse MW, Paschke R, Stumvoll M, Blüher M: Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance. Eur J Endocrinol 154:577–585,2006

DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:214–223,1979

Blüher M, Unger R, Rassoul F, Richter V, Paschke R: Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or type II diabetes. Diabetologia 45:210–216,2002

Björntorp P: Metabolic implication of body fat distribution. Diabetes Care 14:1132–1143,1991

Frayn KN: Visceral fat and insulin resistance-causative or correlative?British J Nutr 83 (Suppl. 1):71–77,2000

Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738,2000

Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P: Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47:913–917,1998

Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, Byrne CD, O'Rahilly S: Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384–1391,1998

Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I: Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860–867,1997

Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M, Kahn BB: Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6:79–87,2007

Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissue of obese sunjects release interleukin 6: depot difference and regulation by glucocorticoid. J Clin Endicrinol Metab 83:847–850,1998

Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima fatty (OLETF) strain. Diabetes 41:1422–1428,1992

Horn R, Geldszus R, Potter E, von zur Muhlen A, Brabant G: Radioimmunoassay for the detection of leptin in human serum. Exp Clin Endocrinol Diabetes 104:454–458,1996

Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M: Radioimmunoassay of leptin in human plasma. Clin Chem 42:942–946,1996

Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741,2002

Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH: The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156:595–602,2007

Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA: Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism 52:939–944,2003

Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 391044–1048,1990

Rydzewski A, Sakata K, Kobayashi A, Yamazaki N, Urano T, Takada Y, Takada A: Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease. Haemostasis 20:305–312,1990

Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K: Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 16:381–385,1996

Ogata N, Matsuoka M, Matsuyama K, Shima C, Tajika A, Nishiyama T, Wada M, Jo N, Higuchi A, Minamino K, Matsunaga H, Takeda T, Matsumura M: Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab 92:1176–1179,2007

Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, Hino A, Jinnouchi Y, Takenaka K, Matsui T, Nakamura K, Imaizumi T: Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 91:2447–2450,2006